Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN060 in Patients With End Stage Renal Disease Receiving Regular Hemodialysis

NCT07201467 is registered in ClinicalTrials.gov with Suzhou Alphamab Co., Ltd. as lead sponsor.

NCT NCT07201467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07201467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN060 in Patients With End Stage Renal Disease Receiving Regular Hemodialysis
Lead sponsor
Suzhou Alphamab Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 22, 2025
Completion date
December 15, 2027
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

end-stage renal disease requiring haemodialysis